Department of Emergency Medicine, University of Florida College of Medicine, Jacksonville, Florida, USA.
Center for Data Solutions, University of Florida College of Medicine, Jacksonville, Florida, USA.
Acad Emerg Med. 2024 Jan;31(1):49-60. doi: 10.1111/acem.14813. Epub 2023 Oct 19.
In the emergency department (ED), prompt administration of systemic corticosteroids for pediatric asthma exacerbations decreases hospital admission rates. However, there is sparse evidence for whether earlier administration of systemic corticosteroids by emergency medical services (EMS) clinicians, prior to ED arrival, further improves pediatric asthma outcomes.
Early Administration of Steroids in the Ambulance Setting: An Observational Design Trial is a multicenter, observational, nonrandomized stepped-wedge design study with seven participating EMS agencies who adopted an oral systemic corticosteroid (OCS) into their protocols for pediatric asthma treatment. Using univariate analyses and multivariable mixed-effects models, we compared hospital admission rates for pediatric asthma patients ages 2-18 years before and after the introduction of a prehospital OCS and for those who did and did not receive a systemic corticosteroid from EMS.
A total of 834 patients were included, 21% of whom received a systemic corticosteroid from EMS. EMS administration of systemic corticosteroids increased after the introduction of an OCS from 14.7% to 28.1% (p < 0.001). However, there was no significant difference between hospital admission rates and ED length of stay before and after the introduction of OCS or between patients who did and did not receive a systemic corticosteroid from EMS. Mixed-effects models revealed that age 14-18 years (coefficient -0.83, p = 0.002), EMS administration of magnesium (coefficient 1.22, p = 0.04), and initial EMS respiratory severity score (coefficient 0.40, p < 0.001) were significantly associated with hospital admission.
In this multicenter study, the addition of an OCS into EMS agency protocols for pediatric asthma exacerbations significantly increased systemic corticosteroid administration but did not significantly decrease hospital admission rates. As overall EMS systemic corticosteroid administration rates were low, further work is required to understand optimal implementation of EMS protocol changes to better assess potential benefits to patients.
在急诊科(ED),及时给予全身皮质类固醇治疗儿童哮喘发作可降低住院率。然而,关于急诊医疗服务(EMS)临床医生在到达 ED 之前更早给予全身皮质类固醇是否进一步改善儿童哮喘结局的证据很少。
在救护车环境中早期给予类固醇:这是一项多中心、观察性、非随机阶梯式楔形设计研究,涉及 7 家参与 EMS 机构,他们在儿科哮喘治疗方案中采用了口服全身皮质类固醇(OCS)。使用单变量分析和多变量混合效应模型,我们比较了在引入院前 OCS 前后 2-18 岁儿科哮喘患者的住院率,以及接受和未接受 EMS 全身皮质类固醇治疗的患者的住院率。
共纳入 834 例患者,其中 21%的患者接受了 EMS 全身皮质类固醇治疗。在引入 OCS 后,EMS 给予全身皮质类固醇的比例从 14.7%增加到 28.1%(p<0.001)。然而,在引入 OCS 前后,以及在接受和未接受 EMS 全身皮质类固醇治疗的患者之间,住院率和 ED 住院时间均无显著差异。混合效应模型显示,年龄 14-18 岁(系数-0.83,p=0.002)、EMS 给予镁(系数 1.22,p=0.04)和初始 EMS 呼吸严重程度评分(系数 0.40,p<0.001)与住院显著相关。
在这项多中心研究中,将 OCS 添加到 EMS 机构儿科哮喘发作的治疗方案中,显著增加了全身皮质类固醇的使用,但并未显著降低住院率。由于总体 EMS 全身皮质类固醇使用率较低,需要进一步研究以了解优化 EMS 方案变更的实施情况,从而更好地评估对患者的潜在益处。